Oncology Institute (NASDAQ:STLN) Major Shareholder Acquires $78,480.00 in Stock

Oncology Institute, Inc. (NASDAQ:STLN) major shareholder Jorey Chernett acquired 12,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The shares were acquired at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the completion of the transaction, the insider directly owned 10,660,858 shares of the company’s stock, valued at $69,722,011.32. The trade was a 0.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Oncology Institute Stock Up 4.1%

Shares of Oncology Institute stock opened at $6.66 on Thursday. Oncology Institute, Inc. has a twelve month low of $2.32 and a twelve month high of $7.05.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings initiated coverage on shares of Oncology Institute in a research note on Thursday, August 6th. They issued a “sell (d-)” rating for the company. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Oncology Institute has a consensus rating of “Sell”.

About Oncology Institute

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.